Abstract
The prognosis of patients with non-GCB DLBCL is poor, especially in those with extranodal invasion which has strong invasiveness and rapid clinical progress. How to improve the prognosis of these patients is the main challenge of DLBCL therapy. Bruton tyrosine kinase (BTK) is a member of the non-receptor tyrosine kinase Tec family; it is involved in the proliferation, adhesion and metastasis of B cells. BTK inhibitor showed activity in relapsed/refractory non-GCB DLBCL. Orelabrutinib is a new oral covalent BTK inhibitor; this study aimed to analyze the efficacy and safety of orelabrutinib plus RCHOP for previously untreated non-GCB DLBCL patients with extranodal disease.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
